About Personal Genome
Personal Genome is a company based in Baltimore (United States) founded in 2010 was acquired by LabCorp in December 2021. Personal Genome has raised $327.45 million across 10 funding rounds from investors including LabCorp, Inova and TD Securities. Personal Genome operates in a competitive market with competitors including MedGenome, Foundation Medicine, Personalis, Veritas Genetics and NeoGenomics, among others.
- Headquarter Baltimore, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Personal Genome Diagnostics Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Personal Genome
Unlock access to complete
Funding Insights of Personal Genome
Personal Genome has successfully raised a total of $327.45M across 10 strategic funding rounds. The most recent funding activity was a Series C round of $103 million completed in February 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Personal Genome
Personal Genome has secured backing from 18 investors, including institutional and venture fund investors. Prominent investors backing the company include LabCorp, Inova and TD Securities.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments in medical technology are made by Vensana Capital.
|
Locked | Locked | Locked | |
|
Early-stage and late-stage biotech and finance companies are funded.
|
Locked | Locked | Locked | |
|
Venture capital is provided to biomedical technology startups.
|
Locked | Locked | Locked |
Investor details for Personal Genome
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Personal Genome
Investment portfolio details for Personal Genome
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Personal Genome
Detailed financials for Personal Genome
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Personal Genome Comparisons
Peer comparison for Personal Genome
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Personal Genome
Personal Genome operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as MedGenome, Foundation Medicine, Personalis, Veritas Genetics and NeoGenomics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
DNA sequencing, bioinformatics, and multiomics services are provided.
|
|
| Locked | Locked | Locked |
Genomics-based diagnostic tests for cancer are provided.
|
|
| Locked | Locked | Locked |
Genomic sequencing and diagnosis software is provided for healthcare.
|
|
| Locked | Locked | Locked |
Genetic testing products for health risks and traits are offered.
|
|
| Locked | Locked | Locked |
Cancer genetic diagnostic services are provided through specialized lab networks.
|
|
| Locked | Locked | Locked |
Non-invasive biomarker tests for colorectal cancer are developed.
|
Detailed competitors of Personal Genome
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Personal Genome
Complete news archive for Personal Genome
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Personal Genome
Personal Genome was founded in 2010 and raised its 1st funding round 1 year after it was founded.
Personal Genome is headquartered in Baltimore, United States. It is registered at Baltimore, Maryland, United States.
Personal Genome is a funded company, having raised a total of $327.45M across 10 funding rounds to date.
Founded in 2010 and based in Baltimore, United States, Personal Genome operates in the biotechnology sector focused on oncology. Proprietary techniques have been developed to detect tumor mutations via analysis of circulating tumor DNA. CLIA certification is held for high-complexity molecular testing, encompassing whole exome sequencing, targeted panels, and plasma-based approaches to support clinical diagnostics.
Personal Genome's top competitors include Foundation Medicine, MedGenome and Personalis.
Personal Genome has 18 investors. Key investors include LabCorp, Inova, TD Securities, Bristol-Myers Squibb, and Vensana Capital.